

## **Shionogi Received “2020 Award for Excellence in Corporate Disclosure” for four Consecutive Year from the Securities Analysts Association of Japan (SAAJ)**

---

**OSAKA, Japan, November 9, 2020** - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi received 2020 Award for Excellence in Corporate Disclosure from the Securities Analysts Association of Japan (SAAJ). Shionogi ranked first in the pharmaceuticals sector. This is the four consecutive year that Shionogi has received this award.

The main points that we were highly evaluated for this award are as follows.

- Managements' proactive involvement in IR that emphasizes dialogue with the market and utilizes the knowledge and opinions gained in management
- Sufficient information is gathered in the IR group, and useful dialogue with IR personnel is possible
- Publication of the medium-term Business plan and long-term vision, and full explanation of subsequent progress and concrete measures for achievement
- Active integrated disclosure attitude combining financial and non-financial information in order to improve our corporate value over the medium to long term
  - Ex: R&D Meeting etc.

Upon receiving the award, Isao Teshirogi, President and CEO of Shionogi, stated as follows.

"We are sincerely honored to have received a very prestigious award for the fourth consecutive year. Despite the fact that our business performance in the fiscal year ending March 2020 was challenging, we were selected for this award again because we have honestly continued our "basic stance on IR." "Our basic stance on IR" is to disclose the current issues and measures for solving them to the outside in detail, to actively engage in dialogue with stakeholders, and to take the voice of the stock market seriously without a one-sided explanation, and utilize it in management. We take this award as an ale from our stakeholders in the stock market to our company. Based on our basic stance on IR, we will strive to meet their needs through constructive dialogue so that we can meet the expectations of our stakeholders in the stock market.

Shionogi aims to continuously keep having balanced dialogues with our all stakeholders such as our shareholders/investors, our customers, our surrounding society and our employees with a view to combining our sustainable growth with our society's sustainable growth. We continuously strive to improve our high-level disclosure even more in order to deepen dialogues that lead to make our corporate value higher.

# Press Release



2017 Award for Excellence  
in Corporate Disclosure

— Industries —

**SAAJ** The Securities Analysts  
Association of Japan



2018 Award for Excellence  
in Corporate Disclosure

— Industries —

**SAAJ** The Securities Analysts  
Association of Japan



2019 Award for Excellence  
in Corporate Disclosure

— Industries —

**SAAJ** The Securities Analysts  
Association of Japan



2020 Award for Excellence  
in Corporate Disclosure

— Industries —

**SAAJ** The Securities Analysts  
Association of Japan

## Excellence in Corporate Disclosure

This award aims to promote the quality and fairness of corporate disclosure from the view point of securities analysts, which was established by SAAJ in 1995. For more information, please visit the website at <http://www.saa.or.jp/english/research/disclosure.html>.

On this web, you can also see a video message for about 3 minutes by Isao Teshiroki, President and CEO of Shionogi.

## Forward-Looking Statements

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

## For Further Information, Contact:

Corporate Communications Department  
Shionogi & Co., Ltd.  
Telephone: +81-6-6209-7885